Evidence map›Paper›PMID 41400715›Full record

ArticleBreast cancer research and treatment2025

Trimodal therapy is associated with higher overall survival than chemotherapy only in patients with metastatic inflammatory breast cancer.

Eric Schupp, Yevgeniya Gokun, Jacob Eckstein, Daniel G Stover, Sachin Jhawar, Dionisia Quiroga, Margaret E Gatti-Mays, Mathew Cherian, Min-Jeong Cho, Kai C C Johnson and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Eric SchuppDivision of Surgical Oncology, Department of Surgery, The Ohio State University, N924 Doan Hall, 410 West 10th, Columbus, OH, USA.
Yevgeniya GokunCenter for Biostatistics, College of Medicine, The Ohio State University, Columbus, OH, USA.
Jacob EcksteinDepartment of Radiation Oncology, The Ohio State University, Columbus, OH, USA.
Daniel G StoverDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Sachin JhawarDepartment of Radiation Oncology, The Ohio State University, Columbus, OH, USA.
Dionisia QuirogaDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Margaret E Gatti-MaysDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Mathew CherianDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Min-Jeong ChoDepartment of Plastic and Reconstructive Surgery, The Ohio State University, Columbus, OH, USA.
Kai C C JohnsonDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Heather LeFebvreDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
J C ChenDivision of Surgical Oncology, Department of Surgery, The Ohio State University, N924 Doan Hall, 410 West 10th, Columbus, OH, USA.
Mohamed I ElsaidCenter for Biostatistics, College of Medicine, The Ohio State University, Columbus, OH, USA.
Samilia Obeng-GyasiDivision of Surgical Oncology, Department of Surgery, The Ohio State University, N924 Doan Hall, 410 West 10th, Columbus, OH, USA. samilia.obeng-gyasi@osumc.edu.ORCID http://orcid.org/0000-0002-5330-7247

Funding

American Cancer Society RSG-22-106-01-CSCT
6 · The paper itself

Abstract

purposeSystemic therapy is standard for metastatic inflammatory breast cancer (MIBC), but the role of locoregional therapy in survival remains unclear. The objective of this study was to compare overall survival (OS) between patients with MIBC who received trimodal therapy vs chemotherapy alone.

methodsPatients diagnosed with MIBC between 2004 and 2021 were identified in the NCDB. The cohort was divided into those who received trimodal therapy vs chemotherapy only. Trimodal therapy included receipt of chemotherapy, surgery (modified radical or radical mastectomy), and radiation therapy. Overlap Propensity Score Weighted Cox proportional hazard models examined the association between treatment (chemotherapy versus trimodal therapy) and OS.

resultsA total of 2872 patients with MIBC were included, of whom 403 (14.0%) underwent trimodal therapy and 2469 (86.0%) received chemotherapy alone. Median OS was longer with trimodality therapy than with chemotherapy alone (47.0 months vs 34.4 months, p < 0.001). Receiving trimodal therapy was associated with a 28% lower hazard of mortality compared to chemotherapy only (aHR: 0.72, 95% CI 0.62-0.84).

conclusionsIn this NCDB cohort of patients with MIBC, receipt of trimodal therapy improved OS compared with chemotherapy only.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsInflammatory Breast NeoplasmsAdultAgedCombined Modality TherapyFemaleHumansMiddle AgedNeoplasm MetastasisRetrospective StudiesTreatment OutcomeChemotherapyMetastatic inflammatory breast cancerOverall survivalTrimodal therapy

Identifiers

PMID41400715

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.